GENOWAY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.19 EUR | -0.95% |
|
-3.01% | -8.91% |
| 2023 | GenOway: sharp rise, broker initiates buy recommendation | CF |
| 2023 | GENOWAY : Euroland initiates buy coverage | CF |
| Sales 2021 | 19.59M 21.25M | Sales 2022 | 21.09M 22.87M | Capitalization | 35.3M 38.28M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | 2.2 x |
| Net Debt 2021 | 5.22M 5.66M | Net Debt 2022 | 4.16M 4.51M | EV / Sales 2022 | 1.87 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | 124 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 72.58% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.95% | ||
| 1 week | -3.01% | ||
| 1 month | +0.96% | ||
| 3 months | +9.11% | ||
| 6 months | +0.96% | ||
| Current year | -8.91% |
1 week
4.17
4.34
1 month
4.064.44
Current year
3.724.91
1 year
3.504.91
3 years
2.644.91
5 years
1.007.70
10 years
1.007.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Founder | - | 99-02-28 | |
Benjamin Bruneau
DFI | Director of Finance/CFO | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 99-02-28 | |
Raffy Kazandjian
BRD | Director/Board Member | - | - |
Patrick Blain
BRD | Director/Board Member | 72 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.19 | -0.95% | 3,942 |
| 24-05-30 | 4.23 | -1.17% | 10,225 |
| 24-05-29 | 4.28 | +1.66% | 10,042 |
| 24-05-28 | 4.21 | -2.09% | 8,667 |
| 24-05-27 | 4.3 | -0.46% | 6,188 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
genOway est une société de biotechnologie spécialisée dans la conception et le développement de modèles de recherche moléculaires, cellulaires et animaux à forte valeur ajoutée pour les industries biopharmaceutique, chimique, agrochimique et agroalimentaire ainsi que pour la recherche académique. genOway est une société leader sur son marché. Elle appuie son développement sur la combinaison d'une large et exclusive plateforme technologique et d'une propriété intellectuelle forte combinant brevets et licences d'exploitation. genOway a conclu de nombreux contrats commerciaux avec les leaders de l'industrie pharmaceutique (BMS, Janssen, Novartis, Pfizer, etc.), et avec les centres de recherche académiques les plus prestigieux (King's College et Université de Manchester en Angleterre, Harvard, Caltech et le National Institute of Health aux Etats-Unis, l'Institut Pasteur en France, le NGFN et l'Institut Max Planck en Allemagne, etc.).
Calendar
2024-06-27
- Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -8.91% | 40.95M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ALGEN Stock
